SG11202109290YA - Threonine166 and serine189 of rubicon run domain as lrrk2 kinase inhibition target sites - Google Patents

Threonine166 and serine189 of rubicon run domain as lrrk2 kinase inhibition target sites

Info

Publication number
SG11202109290YA
SG11202109290YA SG11202109290YA SG11202109290YA SG11202109290YA SG 11202109290Y A SG11202109290Y A SG 11202109290YA SG 11202109290Y A SG11202109290Y A SG 11202109290YA SG 11202109290Y A SG11202109290Y A SG 11202109290YA SG 11202109290Y A SG11202109290Y A SG 11202109290YA
Authority
SG
Singapore
Prior art keywords
serine189
rubicon
target sites
kinase inhibition
lrrk2 kinase
Prior art date
Application number
SG11202109290YA
Inventor
Lai Ling Sharon Chan
Eng King Tan
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of SG11202109290YA publication Critical patent/SG11202109290YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202109290YA 2019-03-07 2020-03-06 Threonine166 and serine189 of rubicon run domain as lrrk2 kinase inhibition target sites SG11202109290YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201902046S 2019-03-07
PCT/SG2020/050113 WO2020180257A1 (en) 2019-03-07 2020-03-06 Threonine166 and serine189 of rubicon run domain as lrrk2 kinase inhibition target sites

Publications (1)

Publication Number Publication Date
SG11202109290YA true SG11202109290YA (en) 2021-09-29

Family

ID=72338780

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109290YA SG11202109290YA (en) 2019-03-07 2020-03-06 Threonine166 and serine189 of rubicon run domain as lrrk2 kinase inhibition target sites

Country Status (5)

Country Link
US (1) US20220169720A1 (en)
EP (1) EP3935082A4 (en)
CN (1) CN113710700A (en)
SG (1) SG11202109290YA (en)
WO (1) WO2020180257A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3872170A1 (en) * 2020-02-25 2021-09-01 University of Georgia Research Foundation, Inc. Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (lrrk2)
JP7486669B2 (en) 2020-10-26 2024-05-17 インダストリー‐ユニバーシティー コーぺレーション ファンデーション ハンヤン ユニバーシティ エリカ キャンパス Biomarkers for the diagnosis of tuberculosis, nontuberculous mycobacterial infections, and latent tuberculosis and their uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010030936A2 (en) * 2008-09-12 2010-03-18 Mount Sinai School Of Medicine Of New York University Novel autophagy regulators atg14l and rubicon
EP2385071A1 (en) * 2008-12-04 2011-11-09 Yeda Research And Development Co. Ltd. Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases related to beclin-1
WO2014046966A1 (en) * 2012-09-24 2014-03-27 Board Of Regents, The University Of Texas System Beclin 1 phosphorylation
WO2020022499A1 (en) * 2018-07-27 2020-01-30 国立大学法人大阪大学 Composition for inhibiting aging, preventing, improving, or treating age-related diseases, or extending lifespan

Also Published As

Publication number Publication date
EP3935082A4 (en) 2023-01-11
US20220169720A1 (en) 2022-06-02
WO2020180257A1 (en) 2020-09-10
CN113710700A (en) 2021-11-26
EP3935082A1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
SG11202106635WA (en) Combination of antibody-drug conjugate and kinase inhibitor
IL282774A (en) Expansion of tils utilizing akt pathway inhibitors
EP3573623A4 (en) Compositions and methods for inhibition of factor xii gene expression
EP3806858A4 (en) Kinase inhibitor salts and compositions thereof
IL271109A (en) Imidazole-containing inhibitors of alk2 kinase
EP3768267A4 (en) Kinase inhibitor compounds and compositions and methods of use
EP3668839A4 (en) Heterocyclic inhibitors of atr kinase
EP3651768A4 (en) Heterocyclic inhibitors of atr kinase
EP3962908A4 (en) Heterocyclic inhibitors of tyrosine kinase
SG11202109290YA (en) Threonine166 and serine189 of rubicon run domain as lrrk2 kinase inhibition target sites
IL279586A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
SG11202008925VA (en) Inhibitors of micro-rna 22
EP3250192A4 (en) Compositions and methods of using tyrosine kinase inhibitors
IL283599A (en) Tyrosine kinase inhibitors, compositions and methods there of
EP3765008A4 (en) Heterocyclic inhibitors of atr kinase
EP3402521A4 (en) Inhibition of allergic reaction using an il-33 inhibitor
EP3906028A4 (en) Kinase inhibitor compounds and compositions and methods of use
EP3906233A4 (en) Kinase inhibitor compounds and compositions and methods of use
EP3405576A4 (en) Methods and compositions using rna interference for inhibition of kras
EP3661552A4 (en) Compositions and methods for inhibition of mica/b shedding
EP3768301A4 (en) Compositions and methods of fas inhibition
EP3573955A4 (en) Compounds for inhibiting lrrk2 kinase activity
EP3787655A4 (en) Compositions and methods related to rhamnus prinoides (gesho) extract for the inhibition of polymicrobial biofilm formation
EP3687514A4 (en) Methods and compositions for inhibition of stat3
EP3990442C0 (en) Rho kinase inhibitors and compositions and methods of use thereof